Netramark Signs Contract with a Leading Global Biopharmaceutical Company to Enhance Clinical Trial Insights
TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytic
(Financial Post, 2025-11-03T13:34:54Z)